| Literature DB >> 32268618 |
Gabriele Rocchetti1, Biancamaria Senizza1, Gianluca Giuberti1, Domenico Montesano2, Marco Trevisan1, Luigi Lucini1.
Abstract
In this work, different commercial extra-virgin olive oils (EVOO) were subjected to in vitro gastrointestinal digestion and the changes in bioactive compounds were evaluated by ultra-high-pressure liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry, using untargeted metabolomics. As expected, raw EVOO samples were abundant in total sterols (on average: 3007.4 mg equivalents/kg) and tyrosol equivalents (on average: 334.1 mg equivalents/kg). However, the UHPLC-QTOF screening allowed us to annotate 310 compounds, with a large abundance of sterols (219 compounds), followed by polyphenols (67 compounds) and terpenoids. The in vitro gastrointestinal digestion was found to affect the phytochemical composition of the different EVOO samples. In particular, both unsupervised and supervised statistics depicted the modifications of the bioactive profile following gastric and pancreatic phases. Overall, the compounds which resulted as the most affected by the in vitro digestion were flavonoids (cyanidin and luteolin equivalents), whilst relatively high % bioaccessibility values were recorded for tyrosol equivalents during the pancreatic phase (on average, 66%). In this regard, oleuropein-aglycone (i.e., the major phenolic compound in EVOO) was converted to hydroxytyrosol, moving from an average value of 1.3 (prior to the in vitro digestion) up to 9.7 mg equivalents/kg during the pancreatic step. As proposed in the literature, the increase in hydroxytyrosol might be the result of the combined effect of lipase(s) activity and acidic conditions. Taken together, the present findings corroborate the suitability of untargeted metabolomics coupled to in vitro digestion methods to investigate the bioaccessibility of phenolic compounds. In this regard, a significant impact of in vitro gastrointestinal digestion on polyphenolic profiles has been detected, thus suggesting the need to account for actual bioaccessibility values rather than just considering the amounts in the raw commodity.Entities:
Keywords: EVOO; UHPLC-QTOF; foodomics; polyphenols; sterols; tyrosol derivatives
Year: 2020 PMID: 32268618 PMCID: PMC7222208 DOI: 10.3390/antiox9040302
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Unsupervised hierarchical cluster analysis (HCA) for the phytochemical profile of different Extra-Virgin Olive Oil (EVOO) samples T0 (raw; prior to digestion), gastric and pancreatic phases of in vitro gastrointestinal digestion. The cluster was built by considering the fold-change heat-map (similarity: Squared Euclidean; linkage rule: Ward). The color range represents the fold-change values used to build the heat-map.
Figure 2Orthogonal projection to latent structures discriminant analysis (OPLS-DA) score plot showing the modifications of the phytochemical composition of EVOO samples, moving from T0 (raw; prior to digestion) to gastric and pancreatic phases of in vitro gastrointestinal digestion.
VIP (variables importance in projection) markers following supervised OPLS-DA during in vitro gastrointestinal digestion of different EVOO samples. * = confirmed by naïve Bayesian analysis.
| Class | VIP Marker (OPLS-DA) | VIP Score |
|---|---|---|
|
| Dihydrocinchonine | 1.09 ± 0.42 |
|
| L-Tryptophan | 1.10 ± 0.21 |
|
| Halleridone | 1.37 ± 1.71 |
|
| (Z)-3-Hexen-1-ol | 1.16 ± 0.20 |
|
| Pelargonidin 3- | 1.25 ± 0.22 |
| Peonidin * | 1.16 ± 0.20 | |
| Apigenin | 1.08 ± 0.34 | |
| Luteolin * | 1.08 ± 0.31 | |
| Pelargonidin * | 1.08 ± 0.30 | |
| Chrysoeriol 7- | 1.07 ± 0.43 | |
| Cyanidin | 1.07 ± 0.35 | |
| Hispidulin * | 1.07 ± 0.30 | |
| Luteolin 7- | 1.06 ± 0.43 | |
| Delphinidin 3- | 1.06 ± 0.41 | |
| Peonidin 3- | 1.04 ± 0.31 | |
| Cyanidin 3- | 1.04 ± 0.48 | |
| Rhoifolin | 1.03 ± 0.46 | |
| Peonidin 3- | 1.01 ± 0.18 | |
| Apigenin 6- | 1.01 ± 0.23 | |
|
| 8-acetoxy-4’-methoxypinoresinol | 1.64 ± 1.45 |
| (-)-Olivil | 1.15 ± 0.50 | |
| Secoisolariciresinol | 1.08 ± 0.19 | |
|
| Salidroside | 1.21 ± 0.09 |
| Hexanal | 1.16 ± 0.20 | |
|
| Oleuropein * | 1.26 ± 0.91 |
| 3,4-dihydroxyphenylethanol-4-diglucoside | 1.16 ± 0.15 | |
| Oleuropein-aglycone | 1.06 ± 0.73 | |
| Hydroxytyrosol * | 1.05 ± 0.84 | |
| Ligustroside | 1.01 ± 0.23 | |
|
| 4-hydroxybenzoic acid * | 2.12 ± 0.77 |
| Coumaric acid | 1.11 ± 0.21 | |
| Cinnamic acid | 1.04 ± 0.24 | |
|
| (S)-Oleuropeic acid | 1.26 ± 1.05 |
| Oleuroside | 1.26 ± 0.92 | |
| 3β-Myrianthic acid | 1.04 ± 0.24 | |
|
| Pyridoxine | 1.01 ± 0.22 |
|
| Hellebrigenin | 1.08 ± 0.89 |
| Scillarenin | 1.03 ± 0.25 | |
|
| Cannogenin | 1.11 ± 0.38 |
|
| 7-oxo-cholestenone | 1.14 ± 0.19 |
| 19-norcholestenone | 1.11 ± 0.17 | |
| Cholest-7-en-3β,5α,6β,9α-tetrol | 1.10 ± 0.23 | |
| 24-northornasterol A | 1.10 ± 0.38 | |
| 2α,7β,15β,18-tetraacetoxy-cholest-5-en-3α-ol * | 1.09 ± 0.21 | |
| 2-deoxy-20-hydroxy-5α-ecdysone 3-acetate | 1.07 ± 0.47 | |
| 2-deoxyecdysone 22-phosphate | 1.07 ± 0.29 | |
| 20-hydroxyecdysone | 1.06 ± 0.24 | |
| 2-dehydroecdysone | 1.04 ± 0.47 | |
|
| Stoloniferone F | 1.09 ± 0.28 |
| Typhasterol | 1.04 ± 0.30 | |
| Makisterone B | 1.02 ± 0.29 | |
| Nebrosteroid L * | 1.00 ± 0.34 | |
|
| Episceptrumgenin | 1.16 ± 0.19 |
| 3- | 1.10 ± 0.25 | |
| (23S,24R,25S)-23,24-dihydroxy-spirost-5-en-3β-yl- | 1.08 ± 0.36 | |
| Agavegenin A | 1.08 ± 0.30 | |
| 6- | 1.04 ± 0.27 | |
| 3- | 1.02 ± 0.31 | |
|
| Norselic acid A | 1.07 ± 0.39 |
| Norselic acid E | 1.06 ± 0.49 | |
|
| Proscillaridin A | 2.67 ± 0.72 |
| Minabeolide-8 | 1.18 ± 0.03 | |
| 15β-Hydroxynicandrin B | 1.01 ± 0.45 | |
| Minabeolide-5 | 1.00 ± 0.49 |
Semi-quantitative contents of polyphenols and sterols (expressed as mean value, n = 3) in EVOO samples prior to the in vitro digestion (T0), together with their changes during in vitro gastrointestinal digestion, considering both gastric and pancreatic phases. The % bioaccessibility value for each digestion phase is reported in round brackets.
| Equivalents | EVOO | T0 (mg/kg) | Gastric Phase (mg/kg) | Pancreatic Phase (mg/kg) |
|---|---|---|---|---|
|
| Frantoio | 0.17 | 0.01 (8%) | 0.02 (14%) |
| Leccino | 0.22 | 0.01 (4%) | 0.02 (10%) | |
| Picholine | 0.08 | 0.01 (12%) | 0.03 (33%) | |
| Kalamon | 0.20 | 0.01 (6%) | 0.02 (10%) | |
| Picual | 0.15 | 0.01 (8%) | 0.02 (15%) | |
|
| Frantoio | 0.59 | 0.00 (1%) | 0.01 (1%) |
| Leccino | 0.73 | 0.00 (0%) | 0.01(1%) | |
| Picholine | 0.30 | 0.00 (1%) | 0.00(2%) | |
| Kalamon | 0.58 | 0.00 (1%) | 0.01(1%) | |
| Picual | 0.46 | 0.01 (2%) | 0.01(2%) | |
|
| Frantoio | 11.83 | 0.77 (7%) | 0.71 (6%) |
| Leccino | 5.30 | 0.98 (18%) | 0.71 (13%) | |
| Picholine | 6.72 | 0.75 (11%) | 1.16 (17%) | |
| Kalamon | 6.18 | 1.39 (22%) | 1.13 (18%) | |
| Picual | 8.80 | 0.67 (8%) | 0.91 (10%) | |
|
| Frantoio | 248.25 | 138.18 (56%) | 189.81 (76%) |
| Leccino | 259.72 | 142.57 (55%) | 201.86 (78%) | |
| Picholine | 252.37 | 164.12 (65%) | 196.46 (78%) | |
| Kalamon | 556.28 | 244.72 (44%) | 191.79 (34%) | |
| Picual | 353.74 | 162.04 (46%) | 212.56 (60%) | |
|
| Frantoio | 13.81 | 1.66 (12%) | 1.38 (10%) |
| Leccino | 10.13 | 1.73 (17%) | 1.84 (18%) | |
| Picholine | 9.80 | 1.09 (11%) | 1.29 (13%) | |
| Kalamon | 9.20 | 1.46 (16%) | 1.30 (14%) | |
| Picual | 6.75 | 1.69 (25%) | 1.43 (21%) | |
|
| Frantoio | 2020.86 | 194.51 (10%) | 221.22 (11%) |
| Leccino | 3706.94 | 135.82 (4%) | 188.00 (5%) | |
| Picholine | 3592.74 | 150.85 (4%) | 263.46 (7%) | |
| Kalamon | 2617.99 | 205.50 (8%) | 248.45 (9%) | |
| Picual | 3098.74 | 161.06 (5%) | 271.07 (9%) |
Figure 3Main changes during in vitro gastrointestinal digestion involving oleuropein, oleuropein-aglycone and hydroxytyrosol in the different EVOO samples. (A) Frantoio, (B) Kalamon, (C) Leccino, (D) Picholine, (E) Picual.